Clinical Trials on Infections, Human Immunodeficiency Virus and Tuberculosis
Total 24649 results
-
GlaxoSmithKlineCompletedHIV Infection | HIV-1 Infection | Infection, Human Immunodeficiency Virus INetherlands, Finland, Ireland, Portugal, Switzerland
-
Merck Sharp & Dohme LLCWithdrawnHuman Immunodeficiency Virus (HIV) Infections
-
Walter K. KraftMerck Sharp & Dohme LLCCompletedLatent Tuberculosis | Human Immunodeficiency Virus | Drug Interaction Potentiation | Rifamycins Causing Adverse Effects in Therapeutic UseUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
International AIDS Vaccine InitiativeTargeted Genetics CorporationCompletedHIV Infections | Human Immunodeficiency Virus InfectionsUganda, South Africa, Zambia
-
ViiV HealthcareTerminatedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
-
GlaxoSmithKlineCompletedHIV Infection | Infection, Human Immunodeficiency Virus IGermany, Belgium, United Kingdom, Spain, Ireland, Italy, France, Austria, Denmark, Netherlands, Switzerland, Portugal, Latvia
-
Shenzhen Immuno Cure Biomedical Company LimitedShenzhen Third People's HospitalActive, not recruitingHuman Immunodeficiency Virus | Human Immunodeficiency Virus I InfectionChina
-
George Washington UniversityCompletedInfluenza, Human | Human Immunodeficiency Virus I InfectionUnited States
-
GlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
GlaxoSmithKlineUniversity GhentCompletedHIV Infections | Infection, Human Immunodeficiency VirusBelgium
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusFrance, Germany, United States, Canada, Belgium, Austria, Brazil, Italy, Poland
-
ViiV HealthcareCompletedHIV Infections | Infection, Human Immunodeficiency VirusUnited States
-
Georgetown UniversityGlaxoSmithKlineCompletedHuman Immunodeficiency Virus InfectionsUnited States
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Spain, Germany, Canada, Belgium, Portugal, Italy, France, United Kingdom
-
ViiV HealthcareCompletedHIV Infection | Infection, Human Immunodeficiency Virus IUnited States, Puerto Rico, Costa Rica, Panama
-
ViiV HealthcareTerminatedHIV-1 Infection | Infection, Human Immunodeficiency Virus IUnited States, France, Germany, Canada, Italy, Australia, Belgium, Portugal, Puerto Rico, Romania, United Kingdom
-
GlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus | HIV-1 InfectionUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV-1 Infection | Infection, Human Immunodeficiency Virus IGermany, Spain, France, Belgium, United Kingdom, Italy, Romania, Russian Federation, Switzerland
-
RetroLead (Shanghai) BioPharma Co., Ltd.Not yet recruitingHuman Immunodeficiency Virus-1 (HIV-1) Infection
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency Virus IUnited States, Canada, Puerto Rico
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusGermany
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfection, Human Immunodeficiency Virus IUnited States, Spain, Germany, Australia, Canada, Belgium, Denmark, Netherlands, United Kingdom, France, Italy, Romania
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited Kingdom
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
GlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency Virus
-
ViiV HealthcareCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxosmithkline/QuintilesCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; PPDCompletedInfection, Human Immunodeficiency VirusUnited States, Canada, Puerto Rico
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxoSmithKline; Janssen PharmaceuticalsCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfection, Human Immunodeficiency VirusUnited States, Spain, France, Canada, Portugal, Italy, Belgium
-
ViiV HealthcareGlaxoSmithKlineCompletedEffect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy SubjectsInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfection, Human Immunodeficiency VirusUnited States